不同结果判定标准下胃癌人表皮生长因子受体-2的表达及其与临床病理特征的关系

目的对比在不同的结果判定标准下胃癌人表皮生长因子受体-2(HER-2)的表达情况及其与临床病理学因素的关系。方法回顾分析2009年1月至12月北京大学肿瘤医院外科收治胃癌患者的资料,对手术标本进行切片、免疫组织化学染色。结果采用新的和传统的HER-2免疫组织化学判定标准,HER-2强阳性率(3+)分别为6.7%和3.3%(P=0.076);采用新的免疫组织化学判定标准,HER-2的阳性率(2+和3+)为8.5%。单因素分析显示,HER-2表达与肿瘤分化程度、Lauren分型和肿瘤大小有关;多因素分析发现,肿瘤大小是影响HER-2表达的独立影响因素。结论新旧两种免疫组织化学判定标准下HER-2的阳性率其差异没有统计学意义;HER-2在胃癌中的表达与临床病理特征有密切关系。

Expression of human epidermal growth factor receptor 2 in gastric cancer with different scoring systems and its relationship with clinicopathological features

Objective To compare the expression of human epidermal growth factor receptor-2 (HER-2) by using different scoring systems in gastric cancer and to investigate its relationship with clinicopathological features. Methods Clinicopathological data of 270 patients with gastric cancers between January to December 2009 in the Department of Surgery at Peking University School of Oncology, were retrospectively reviewed. Tumor specimens were collected and the expression of HER-2 protein was detected by immunohistochemistry stainning. Results HER-2 (3+) positive rates were 6.7% and 3.3% respectively by using the new and traditional scoring systems (P=0.076). The HER-2 positive rate (2+/3+) of gastric cancer was 8.5% by using the new immunohistochemical scoring system. Single factor analysis showed that the HER-2 protein has a higher expression rate in large tumor (diameter≥5 cm), highly/moderated differentiated tumor, and intestinal type tumor. Multivariate analysis showed that the tumor size was the independent factor influencing the over expression of HER-2 protein. Conclusion There is no significant difference in the HER-2 (3+) positive rate in gastric cancer by the new and traditional scoring systems. HER-2 over expression is correlated with its clinicopathological features.